264 related articles for article (PubMed ID: 17081806)
21. Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center.
Watt K; Uhanova J; Minuk GY
Am J Gastroenterol; 2002 Aug; 97(8):2046-50. PubMed ID: 12190175
[TBL] [Abstract][Full Text] [Related]
22. [MELD score in prediction of early mortality in patients suffering refractory ascites treated by TIPS].
Fejfar T; Safka V; Hůlek P; Vanásek T; Krajina A; Jirkovský V
Vnitr Lek; 2006 Sep; 52(9):771-6. PubMed ID: 17091599
[TBL] [Abstract][Full Text] [Related]
23. Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study.
Péron JM; Bureau C; Gonzalez L; Garcia-Ricard F; de Soyres O; Dupuis E; Alric L; Pourrat J; Vinel JP
Am J Gastroenterol; 2005 Dec; 100(12):2702-7. PubMed ID: 16393223
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome.
Testro AG; Wongseelashote S; Angus PW; Gow PJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1535-40. PubMed ID: 17784863
[TBL] [Abstract][Full Text] [Related]
25. External validation of a prognostic model for predicting survival of cirrhotic patients with refractory ascites.
Guardiola J; Baliellas C; Xiol X; Fernandez Esparrach G; Ginès P; Ventura P; Vazquez S
Am J Gastroenterol; 2002 Sep; 97(9):2374-8. PubMed ID: 12358259
[TBL] [Abstract][Full Text] [Related]
26. [Hyponatremia as a possible mortality factor in cirrhotic patients hospitalised in the Guillermo Almenara Irigoyen State Hospital, 2003- 2005].
Rafael Valdivia L; Ferrandiz Quiroz J
Rev Gastroenterol Peru; 2007; 27(1):37-46. PubMed ID: 17431435
[TBL] [Abstract][Full Text] [Related]
27. Which patients benefit from hemodialysis therapy in hepatorenal syndrome?
Witzke O; Baumann M; Patschan D; Patschan S; Mitchell A; Treichel U; Gerken G; Philipp T; Kribben A
J Gastroenterol Hepatol; 2004 Dec; 19(12):1369-73. PubMed ID: 15610310
[TBL] [Abstract][Full Text] [Related]
28. Hyponatremia in cirrhosis: Risk factors and prognostic value.
Ennaifer R; Cheikh M; Romdhane H; El Elj R; Ben Nejma H; Bougassas W; Bel Hadj N
Tunis Med; 2016 May; 94(5):401-405. PubMed ID: 27801493
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice.
Salerno F; Cazzaniga M; Merli M; Spinzi G; Saibeni S; Salmi A; Fagiuoli S; Spadaccini A; Trotta E; Laffi G; Koch M; Riggio O; Boccia S; Felder M; Balzani S; Bruno S; Angeli P;
J Hepatol; 2011 Dec; 55(6):1241-8. PubMed ID: 21703199
[TBL] [Abstract][Full Text] [Related]
30. Open-heart surgery in patients with liver cirrhosis: indications, risk factors, and clinical outcomes.
An Y; Xiao YB; Zhong QJ
Eur Surg Res; 2007; 39(2):67-74. PubMed ID: 17283429
[TBL] [Abstract][Full Text] [Related]
31. Incidence and characteristics of type 2 hepatorenal syndrome in patients with cirrhosis and refractory ascites.
Sersté T; Lebrec D; Valla D; Moreau R
Acta Gastroenterol Belg; 2008; 71(1):9-14. PubMed ID: 18396743
[TBL] [Abstract][Full Text] [Related]
32. Factors that predict survival in patients with cirrhosis considered for liver transplantation.
Samada Suarez M; Hernández Perera JC; Ramos Robaina L; Barroso Márquez L; González Rapado L; Cepero Valdés M; Hernández Rivero H; Abdo Cuza A; Valdés AR; Pérez Bernal J; Bernardos A
Transplant Proc; 2008 Nov; 40(9):2965-7. PubMed ID: 19010161
[TBL] [Abstract][Full Text] [Related]
33. [Cox regression analysis of predictive factors of hepatorenal syndrome].
Zhang WJ; Yang DH; Shu JC
Zhonghua Gan Zang Bing Za Zhi; 2003 Oct; 11(10):586-7. PubMed ID: 14572331
[TBL] [Abstract][Full Text] [Related]
34. Influence of coexisting cirrhosis on outcomes after partial hepatic resection for hepatocellular carcinoma fulfilling the Milan criteria: an analysis of 293 patients.
Taura K; Ikai I; Hatano E; Yasuchika K; Nakajima A; Tada M; Seo S; Machimoto T; Uemoto S
Surgery; 2007 Nov; 142(5):685-94. PubMed ID: 17981188
[TBL] [Abstract][Full Text] [Related]
35. Dilutional hyponatremia in patients with cirrhosis and ascites.
Porcel A; Díaz F; Rendón P; Macías M; Martín-Herrera L; Girón-González JA
Arch Intern Med; 2002 Feb; 162(3):323-8. PubMed ID: 11822925
[TBL] [Abstract][Full Text] [Related]
36. Clinical features and survival in Chinese patients with hepatitis B e antigen-negative hepatitis B virus-related cirrhosis.
Ma H; Wei L; Guo F; Zhu S; Sun Y; Wang H
J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1250-8. PubMed ID: 18624896
[TBL] [Abstract][Full Text] [Related]
37. Ascites in cirrhosis: a review of management and complications.
Kuiper JJ; van Buuren HR; de Man RA
Neth J Med; 2007 Sep; 65(8):283-8. PubMed ID: 17890787
[TBL] [Abstract][Full Text] [Related]
38. Type-1 hepatorenal syndrome associated with infections in cirrhosis: natural history, outcome of kidney function, and survival.
Barreto R; Fagundes C; Guevara M; Solà E; Pereira G; Rodríguez E; Graupera I; Martín-Llahí M; Ariza X; Cárdenas A; Fernández J; Rodés J; Arroyo V; Ginès P
Hepatology; 2014 Apr; 59(4):1505-13. PubMed ID: 24037970
[TBL] [Abstract][Full Text] [Related]
39. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study.
Bruno S; Zuin M; Crosignani A; Rossi S; Zadra F; Roffi L; Borzio M; Redaelli A; Chiesa A; Silini EM; Almasio PL; Maisonneuve P
Am J Gastroenterol; 2009 May; 104(5):1147-58. PubMed ID: 19352340
[TBL] [Abstract][Full Text] [Related]
40. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.
Mustea A; Pirvulescu C; Könsgen D; Braicu EI; Yuan S; Sun P; Lichtenegger W; Sehouli J
Cytokine; 2008 Apr; 42(1):77-84. PubMed ID: 18329282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
